Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD

February 17th 2023

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under

February 17th 2023

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17th 2023

Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.

Salvage Checkpoint Inhibitors Reduce Peri-ASCT Progression in R/R Hodgkin Lymphoma

February 17th 2023

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

Orca-T Leads to 100% Survival Rate in Early Trial of Patients With Hematologic Malignancies and 7/8 Mismatched Donors

February 17th 2023

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

Dr. Frank on CD22 CAR T-cell Therapy in Relapsed LBCL

February 17th 2023

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

GvHD: Advice for Patients

February 17th 2023

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

Future of Chronic GvHD

February 17th 2023

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic Malignancies

February 16th 2023

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

Brexu-cel Shows Survival Benefit in Relapsed/Refractory B-cell ALL, Regardless of Prior Treatment

February 16th 2023

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

JCAR021 Showcases High Response Rates, but Mixed Safety Data in Relapsed/Refractory Large B-cell Lymphoma

February 16th 2023

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger

February 16th 2023

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.

Case 2 Discussion and Considerations for Second-Line Treatment Selection

February 16th 2023

The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.

Case 2 Presentation: Lower-Risk MDS-RS With an SF3B1 Mutation

February 16th 2023

Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.

Ponatinib Plus Reduced-Intensity Chemotherapy Steps Up as Potential New SOC in Newly Diagnosed Ph+ ALL

February 15th 2023

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL

February 15th 2023

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Closing Remarks on Advances and Future Directions in MF and MDS

February 15th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Acute Myeloid Leukemia: Frontline Treatment With CPX-351

February 14th 2023

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Role of a Pharmacist in Managing Tumor Lysis Syndrome

February 14th 2023

Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.